These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15181059)

  • 1. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements.
    Biermasz NR; Dekker FW; Pereira AM; van Thiel SW; Schutte PJ; van Dulken H; Romijn JA; Roelfsema F
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2789-96. PubMed ID: 15181059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
    Feelders RA; Bidlingmaier M; Strasburger CJ; Janssen JA; Uitterlinden P; Hofland LJ; Lamberts SW; van der Lely AJ; de Herder WW
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6480-9. PubMed ID: 16159936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.
    Biermasz NR; van Dulken H; Roelfsema F
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
    Serri O; Beauregard C; Hardy J
    J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria.
    Ronchi CL; Varca V; Giavoli C; Epaminonda P; Beck-Peccoz P; Spada A; Arosio M
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1377-82. PubMed ID: 15585548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU; Post KD; Powell JS; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.
    Swearingen B; Barker FG; Katznelson L; Biller BM; Grinspoon S; Klibanski A; Moayeri N; Black PM; Zervas NT
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3419-26. PubMed ID: 9768641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly.
    Biermasz NR; van Dulken H; Roelfsema F
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2476-82. PubMed ID: 10902796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
    Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
    Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
    Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
    Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome.
    Jane JA; Starke RM; Elzoghby MA; Reames DL; Payne SC; Thorner MO; Marshall JC; Laws ER; Vance ML
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2732-40. PubMed ID: 21715544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status.
    Espinosa-de-Los-Monteros AL; Sosa E; Cheng S; Ochoa R; Sandoval C; Guinto G; Mendoza V; Hernández I; Molina M; Mercado M
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):245-9. PubMed ID: 16487431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The common consensus criteria have high predictive values for long-term postoperative acromegaly remission.
    Kristof RA; Grote A; Redel L; Neuloh G; Klingmüller D; Schramm J
    Acta Neurochir (Wien); 2011 Jan; 153(1):19-25. PubMed ID: 20845050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
    Ayuk J; Clayton RN; Holder G; Sheppard MC; Stewart PM; Bates AS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1613-7. PubMed ID: 15070920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.